GLT1 overexpression in SOD1G93A mouse cervical spinal cord does not preserve diaphragm function or extend disease

Neurobiology of Disease

Volumn 78, Issue , 2015, Pages 12-23

  Li, Ke ^a   Hala, Tamara J ^a   Seetharam, Suneil ^a   Poulsen, David J ^b   Wright, Megan C ^c   Lepore, Angelo C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c ARCADIA UNIVERSITY   (United States)

Author keywords

Adeno associated virus; ALS; Amyotrophic laterals sclerosis; Astrocyte; Cervical spinal cord; Diaphragm; Gene therapy; GLT1; Glutamate transporter; Phrenic motor neuron

Indexed keywords

PARVOVIRUS VECTOR; VESICULAR GLUTAMATE TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; SLC1A2 PROTEIN, MOUSE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CERVICAL SPINAL CORD; COMPOUND MUSCLE ACTION POTENTIAL; CONTROLLED STUDY; DIAPHRAGM; DISEASE DURATION; EXCITOTOXICITY; FEMALE; MALE; MOTONEURON; MOTOR CORTEX; MOUSE; MUSCLE ACTION POTENTIAL; NEUROMUSCULAR SYNAPSE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; DISEASE COURSE; DISEASE MODEL; GENE VECTOR; GENETICS; INNERVATION; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; VIROLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASTROCYTES; CERVICAL CORD; DEPENDOVIRUS; DIAPHRAGM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; GENETIC VECTORS; GLUTAMIC ACID; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR NEURONS; SUPEROXIDE DISMUTASE;

EID: 84926339807     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.010     Document Type: Article

References (46)

1. Barbeito L.H., Pehar M., Cassina P., Vargas M.R., Peluffo H., Viera L., Estevez A.G., Beckman J.S. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res. Brain Res. Rev. 2004, 47:263-274.
2. Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., Cleveland D.W. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
3. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., Brown R.H., Julien J.P., Goldstein L.S., Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
4. Davies J.E., Proschel C., Zhang N., Noble M., Mayer-Proschel M., Davies S.J. Transplanted astrocytes derived from BMP- or CNTF-treated glial-restricted precursors have opposite effects on recovery and allodynia after spinal cord injury. J. Biol. 2008, 7:24.
5. +-dependent L-glutamate transport activity in C6 glioma cells by phorbol ester. J. Neurochem. 1996, 67:508-516.
6. Gong Y.H., Parsadanian A.S., Andreeva A., Snider W.D., Elliott J.L. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 2000, 20:660-665.
7. Guo H., Lai L., Butchbach M.E., Stockinger M.P., Shan X., Bishop G.A., Lin C.L. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 2003, 12:2519-2532.
8. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
9. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1604-1609.
10. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
11. Jaarsma D., Teuling E., Haasdijk E.D., De Zeeuw C.I., Hoogenraad C.C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 2008, 28:2075-2088.
12. Kaplan L.M., Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin. Chest Med. 1994, 15:675-681.
13. Lasiene J., Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol. Res. Int. 2011, 2011:718987.
14. Laskowski M.B., Sanes J.R. Topographic mapping of motor pools onto skeletal muscles. J. Neurosci. Off. J. Soc. Neurosci. 1987, 7:252-260.
15. Lepore A.C. Intraspinal cell transplantation for targeting cervical ventral horn in amyotrophic lateral sclerosis and traumatic spinal cord injury. J. Vis. Exp. 2011, 55:1-10.
16. Lepore A.C., Maragakis N.J. Stem cell transplantation for spinal cord neurodegeneration. Methods Mol. Biol. 2011, 793:479-493.
17. Lepore A.C., Walczak P., Rao M.S., Fischer I., Bulte J.W. MR imaging of lineage-restricted neural precursors following transplantation into the adult spinal cord. Exp. Neurol. 2006, 201:49-59.
18. Lepore A.C., Haenggeli C., Gasmi M., Bishop K.M., Bartus R.T., Maragakis N.J., Rothstein J.D. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2007, 1185:256-265.
19. Lepore A.C., Dejea C., Carmen J., Rauck B., Kerr D.A., Sofroniew M.V., Maragakis N.J. Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. Exp. Neurol. 2008, 211:423-432.
20. Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., Maragakis N.J. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008, 11:1294-1301.
21. Lepore A.C., Tolmie C., O'Donnell J., Wright M.C., Dejea C., Rauck B., Hoke A., Ignagni A.R., Onders R.P., Maragakis N.J. Peripheral hyperstimulation alters site of disease onset and course in SOD1 rats. Neurobiol. Dis. 2010, 39:252-264.
22. Lepore A.C., O'Donnell J., Kim A.S., Williams T., Tuteja A., Rao M.S., Kelley L.L., Campanelli J.T., Maragakis N.J. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One 2011, 6:e25968.
23. Lepore A.C., O'Donnell J., Kim A.S., Yang E.J., Tuteja A., Haidet-Phillips A., O'Banion C.P., Maragakis N.J. Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury. Glia 2011, 59:1996-2005.
24. Li K., Nicaise C., Sannie D., Hala T.J., Javed E., Parker J.L., Putatunda R., Regan K.A., Suain V., Brion J.P., Rhoderick F., Wright M.C., Poulsen D.J., Lepore A.C. Overexpression of the astrocyte glutamate transporter GLT1 exacerbates phrenic motor neuron degeneration, diaphragm compromise, and forelimb motor dysfunction following cervical contusion spinal cord injury. J. Neurosci. 2014, 34:7622-7638.
25. Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J. Neurosci. 2002, 22:4825-4832.
26. Maragakis N.J., Rothstein J.D. Glutamate transporters: animal models to neurologic disease. Neurobiol. Dis. 2004, 15:461-473.
27. Maragakis N.J., Rothstein J.D. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2:679-689.
28. Miller R.G., Rosenberg J.A., Gelinas D.F., Mitsumoto H., Newman D., Sufit R., Borasio G.D., Bradley W.G., Bromberg M.B., Brooks B.R., Kasarskis E.J., Munsat T.L., Oppenheimer E.A. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999, 52:1311-1323.
29. Morren J.A., Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs 2012, 21:297-320.
30. Nicaise C., Hala T.J., Frank D.M., Parker J.L., Authelet M., Leroy K., Brion J.P., Wright M.C., Lepore A.C. Phrenic motor neuron degeneration compromises phrenic axonal circuitry and diaphragm activity in a unilateral cervical contusion model of spinal cord injury. Exp. Neurol. 2012, 235:539-552.
31. Pardo A.C., Wong V., Benson L.M., Dykes M., Tanaka K., Rothstein J.D., Maragakis N.J. Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp. Neurol. 2006, 201:120-130.
32. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
33. Pramatarova A., Laganiere J., Roussel J., Brisebois K., Rouleau G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J. Neurosci. 2001, 21:3369-3374.
34. Rothstein J.D., Tsai G., Kuncl R.W., Clawson L., Cornblath D.R., Drachman D.B., Pestronk A., Stauch B.L., Coyle J.T. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 1990, 28:18-25.
35. Rothstein J.D., Martin L.J., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992, 326:1464-1468.
36. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995, 38:73-84.
37. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P., Welty D.F. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
38. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
39. Tandan R., Bradley W.G. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann. Neurol. 1985, 18:271-280.
40. Trotti D., Rolfs A., Danbolt N.C., Brown R.H., Hediger M.A. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat. Neurosci. 1999, 2:427-433.
41. Weller M.L., Stone I.M., Goss A., Rau T., Rova C., Poulsen D.J. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia. Neuroscience 2008, 155:1204-1211.
42. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116.
43. Wright M.C., Son Y.J. Ciliary neurotrophic factor is not required for terminal sprouting and compensatory reinnervation of neuromuscular synapses: re-evaluation of CNTF null mice. Exp. Neurol. 2007, 205:437-448.
44. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
45. Yang Y., Gozen O., Watkins A., Lorenzini I., Lepore A., Gao Y., Vidensky S., Brennan J., Poulsen D., Won Park J., Li Jeon N., Robinson M.B., Rothstein J.D. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 2009, 61:880-894.
46. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.